WuXi Biologics at CPHI Milan 2026: Empowering European Biomanufacturing via Integrated CRDMO & Global Dual Sourcing
At CPHI Milan 2026 (62,000+ professionals, 2,900 exhibitors), WuXi Biologics showcased its integrated CRDMO platform, Global Dual Sourcing strategy and its two European hubs — Dundalk, Ireland (54,000 L) and Wuppertal, Germany — as pillars of supply resilience.
On 9 October 2026, WuXi Biologics showcased its ability to empower European biomanufacturing at CPHI Milan 2026, which brought together more than 62,000 pharmaceutical professionals and 2,900 exhibitors. The European biologics market, valued at an estimated $123.75 billion in 2025, is projected to grow at an 8.1% CAGR from 2026 to 2035, reaching approximately $269.65 billion — underscoring demand for faster development, reliable manufacturing and regional supply resilience.
During the event, WuXi Biologics engaged extensively with global biopharma partners, demonstrating how its innovative technologies advance complex biologics from development to reliable supply. As of June 2026, the company had passed 49 regulatory inspections (including 23 by the FDA and EMA), secured 166 facility license approvals, and passed more than 2,000 GMP quality audits by global clients, including over 280 audits by EU Qualified Persons.
At the core of WuXi Biologics' approach is Global Dual Sourcing, which aligns quality, analytics and technology transfer across its global sites in Ireland, Germany, the US, China and Singapore — enabling manufacturing processes to be transferred, scaled and replicated while maintaining product quality, comparability and execution consistency.
In Europe, the Dundalk, Ireland site is an established commercial manufacturing hub operating under an HPRA GMP license, supporting EMA-approved commercial products, serving 10+ clients and providing 54,000 L of drug-substance capacity; the Wuppertal, Germany site offers flexible development-to-clinical-scale manufacturing — together forming the twin pillars of WuXi Biologics' European supply resilience.